Clinical Trials on Cirrhosis, Liver in Australia

Total 595 results

Medical University of Graz

Completed

Keyhole Limpet Hemocyanin in Chronic Hepatitis C (IM1)

Liver Cirrhosis | Chronic Hepatitis C

Austria
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

Liver Cirrhosis | Hypertension, Portal

Spain, Germany, Canada, China, Austria, United States, Japan, France, Korea, Republic of, Romania
Gilead Sciences

Completed

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Hepatitis C | Cirrhosis | Portal Hypertension | With or Without Liver Decompensation

United States, Spain, New Zealand, Australia, France
Replicor Inc.

Available

Replicor Compassionate Access Program (RCAP)

Decompensated Cirrhosis | Hepatocellular Carcinoma | Cirrhosis, Liver | Ascites Hepatic | Viral Hepatitis B | Viral Hepatitis D | Varices, Esophageal

Austria, France, Israel
Sanofi

Completed

Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites (Hypo~CAT)

Liver Cirrhosis | Ascites

United States, France, Romania, Germany, Italy, Spain, Belgium, Czech Republic, Argentina, Croatia, Hungary, Canada, Australia
CymaBay Therapeutics, Inc.

Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, France, Korea, Republic of, Denmark, Australia, Italy, United Kingdom, Belgium, Canada, Russian Federation, Romania, Germany, Hungary, Mexico, Turkey, Argentina, Austria, Chile, Czechia, Greece, Israel, New Zealand and more
Tobira Therapeutics, Inc.

Terminated

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Liver Cirrhosis | Non-alcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Australia, France, Germany, Spain, Poland, United Kingdom, Italy, Puerto Rico, Belgium, Hong Kong
GlaxoSmithKline

Completed

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

Cholestasis

United States, Australia, France, Spain, Germany, Canada, Japan, United Kingdom, Italy, Poland
Medical University of Graz

Active, not recruiting

Effect of Albumin Infusion on Oxidative Albumin Modification, Albumin Binding Capacity and Plasma Thiol Status (ALB-INFUS)

Decompensated Cirrhosis

Austria
Tobira Therapeutics, Inc.

Terminated

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) (AURORA)

Nonalcoholic Steatohepatitis

United States, Spain, Australia, Belgium, Israel, Canada, Puerto Rico, Italy, Germany, France, New Zealand, Taiwan, Poland, United Kingdom, Brazil, Austria, Singapore, Portugal, Chile, Greece, Hong Kong, Hungary, Latvia, Mexico, Norway, R... and more
Galectin Therapeutics Inc.

Active, not recruiting

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis (NAVIGATE)

Cirrhosis | NASH - Nonalcoholic Steatohepatitis | Prevention of Esophageal Varices

United States, France, Spain, Australia, Canada, Israel, Puerto Rico, Belgium, Argentina, Chile, Germany, Korea, Republic of, Mexico, Poland, United Kingdom
Inipharm Australia Pty Ltd

Recruiting

A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH

Non-alcoholic Steatohepatitis

Australia
Celgene

Terminated

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Liver Cirrhosis | Non-alcoholic Fatty Liver Disease

United States, Spain, Australia, Korea, Republic of, Canada, Germany, France, Japan, United Kingdom, Poland
Eccanga Pty Ltd
Syneos Health

Recruiting

FTIH Study of ECC0509 in Healthy Volunteers

Osteoarthritis | Nonalcoholic Steatohepatitis

Australia
GlaxoSmithKline

Completed

Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

Cirrhosis, Liver

United States, Taiwan, Germany, Israel, Australia, Singapore, Canada, Czechia, Korea, Republic of, Russian Federation, New Zealand, Romania, Puerto Rico, Malaysia
Novo Nordisk A/S

Completed

Use of NovoSeven® in Active Variceal Bleeding

Cirrhosis | Acquired Bleeding Disorder

Germany, United Kingdom, Spain, Taiwan, France, Italy, Austria, Czech Republic, Poland, Denmark, Finland, Hong Kong
Altimmune, Inc.

Completed

ALT-801 DDI Study in Healthy Volunteers

NASH - Nonalcoholic Steatohepatitis

Australia
Medical University of Vienna

Completed

Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC) (AURIC)

Cirrhosis | Chronic Hepatitis C

Austria
Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Completed

The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects

Non-alcoholic Steatohepatitis

Australia
Novartis Pharmaceuticals

Completed

Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis

Hepatitis | Hepatitis B, Chronic | Cirrhosis

United States, France, United Kingdom, Taiwan, Spain, Korea, Republic of, Singapore, New Zealand, Thailand, Germany, Israel, Russian Federation, Canada, China, Latvia, Turkey, Australia, India, Malaysia, Poland, Vietnam
JD Bioscience Inc.
Novotech (Australia) Pty Limited

Enrolling by invitation

First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease

Non-alcoholic Steatohepatitis

Australia
NGM Biopharmaceuticals, Inc

Completed

Study of NGM395 in Adult Participants

Obesity | NAFLD

Australia
Sunshine Lake Pharma Co., Ltd.

Completed

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

Australia
Blade Therapeutics

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects

NASH - Nonalcoholic Steatohepatitis | Chronic Liver Disease

Australia
Syneos Health

Completed

First-in-Human Study of SRT-015 in Healthy Subjects.

Nonalcoholic Steatohepatitis

Australia
Bird Rock Bio, Inc.
Perspectum; ProSciento, Inc.

Completed

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD

United States, Australia, Canada
LISCure Biosciences

Completed

A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants

Rheumatoid Arthritis | Non-Alcoholic Steatohepatitis

Australia
Kirby Institute

Not yet recruiting

The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset

Hepatitis C

Australia
Altimmune, Inc.

Completed

ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

NASH - Nonalcoholic Steatohepatitis

Australia
Enyo Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

Healthy | NASH - Nonalcoholic Steatohepatitis

Australia
AstraZeneca

Completed

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (PROXYMO-ADV)

Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

United States, Austria, Italy, Thailand, Germany, Korea, Republic of, Japan, Malaysia, New Zealand, Spain, Taiwan, Turkey, Australia, Israel, Argentina, Canada, Greece, South Africa, United Kingdom, France
South West Sydney Local Health District
National Health and Medical Research Council, Australia; University of Sydney

Completed

Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease (BacALD)

Alcohol Dependence | Alcoholic Liver Disease

Australia
Gilead Sciences

Terminated

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Hepatitis C Virus Infection

France, Spain, United States, Australia, Canada, Germany, United Kingdom, Italy, New Zealand, Puerto Rico
Phenex Pharmaceuticals AG
Medical University of Vienna

Completed

Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients

Non Alcoholic Fatty Liver Disease

Austria
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer

Liver Cancer

Hong Kong, Taiwan, Singapore, Australia
Medical University of Graz
Fresenius Medical Care North America

Completed

Elimination of Albumin-Bound Substances by MARS and Prometheus

Liver Failure

Austria
Medical University of Vienna
State Government of Vienna, Austria (Medizinisch-Wissenschaftlicher Fonds...

Completed

Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study.

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

Austria
Medical University of Vienna

Unknown

Hepatic Venous Pressure Gradient and Platelet Activation in Chronic Liver Disease

Chronic Liver Disease

Austria
Prof. Michael Trauner, MD
Wiener Wissenschafts-, Forschungs- und Technologiefonds

Unknown

Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

Austria
Medical University of Vienna

Recruiting

Cold-induced Brown Fat Activation and Hepatic Steatosis

Non-Alcoholic Fatty Liver Disease

Austria
Royal North Shore Hospital

Active, not recruiting

Liver Function Investigation With SPECT (LiverINSPECT)

Liver Cancer, Adult

Australia
Kirby Institute

Recruiting

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)

Hepatitis C

Australia
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.

Completed

To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants (XW003)

Obesity | Type 2 Diabetes Mellitus | Nonalcoholic Steatohepatitis

Australia
University of Sydney
Austin Health; Peter MacCallum Cancer Centre, Australia; Western Sydney Local... and other collaborators

Recruiting

Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy (ROCK-RT)

Liver Neoplasm

Australia
Dr. Falk Pharma GmbH

Recruiting

Norursodeoxycholic Acid vs. Placebo in NASH

Nonalcoholic Steatohepatitis

Austria
Medical University of Vienna

Recruiting

Vienna Hypothermic Oxygenated Machine Perfusion Study (VIHOMPS)

End Stage Liver Disease | Hepatocellular Carcinoma

Austria
Mateon Therapeutics

Completed

Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden (OXi4503)

Neoplasm Metastasis

Australia
Hoffmann-La Roche

Completed

A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease

Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD

Germany, Austria
Bayside Health
Gilead Sciences; Centre for Clinical Research Excellence in Infectious Diseases...

Unknown

HIV-HBV Co-Infection and Liver Disease

HIV Infections | HIV-HBV Co-Infection

Australia

Clinical Trials on Cirrhosis, Liver in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations